South Korea · Delayed Price · Currency is KRW Medy-Tox Statistics
Total Valuation
Medy-Tox has a market cap or net worth of KRW 557.19 billion. The enterprise value is 645.02 billion.
| Market Cap | 557.19B |
| Enterprise Value | 645.02B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Medy-Tox has 6.56 million shares outstanding. The number of shares has decreased by -13.18% in one year.
| Current Share Class | 6.56M |
| Shares Outstanding | 6.56M |
| Shares Change (YoY) | -13.18% |
| Shares Change (QoQ) | +12.54% |
| Owned by Insiders (%) | 20.79% |
| Owned by Institutions (%) | 11.38% |
| Float | 5.12M |
Valuation Ratios
The trailing PE ratio is 25.98 and the forward PE ratio is 18.47.
| PE Ratio | 25.98 |
| Forward PE | 18.47 |
| PS Ratio | 2.28 |
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | 10.27 |
| P/OCF Ratio | 8.08 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.64, with an EV/FCF ratio of 11.89.
| EV / Earnings | 32.89 |
| EV / Sales | 2.64 |
| EV / EBITDA | 19.64 |
| EV / EBIT | 50.62 |
| EV / FCF | 11.89 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.01 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 3.24 |
| Debt / FCF | 2.31 |
| Interest Coverage | 28.60 |
Financial Efficiency
Return on equity (ROE) is 4.78% and return on invested capital (ROIC) is 3.93%.
| Return on Equity (ROE) | 4.78% |
| Return on Assets (ROA) | 1.99% |
| Return on Invested Capital (ROIC) | 3.93% |
| Return on Capital Employed (ROCE) | 4.42% |
| Weighted Average Cost of Capital (WACC) | 5.37% |
| Revenue Per Employee | 339.86M |
| Profits Per Employee | 27.31M |
| Employee Count | 718 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.87 |
Taxes
| Income Tax | -8.46B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.35% in the last 52 weeks. The beta is 0.41, so Medy-Tox's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -50.35% |
| 50-Day Moving Average | 99,326.00 |
| 200-Day Moving Average | 116,217.50 |
| Relative Strength Index (RSI) | 37.74 |
| Average Volume (20 Days) | 86,957 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medy-Tox had revenue of KRW 244.02 billion and earned 19.61 billion in profits. Earnings per share was 3,271.97.
| Revenue | 244.02B |
| Gross Profit | 146.54B |
| Operating Income | 18.57B |
| Pretax Income | 11.74B |
| Net Income | 19.61B |
| EBITDA | 38.67B |
| EBIT | 18.57B |
| Earnings Per Share (EPS) | 3,271.97 |
Balance Sheet
The company has 42.53 billion in cash and 125.33 billion in debt, with a net cash position of -82.79 billion or -12,630.27 per share.
| Cash & Cash Equivalents | 42.53B |
| Total Debt | 125.33B |
| Net Cash | -82.79B |
| Net Cash Per Share | -12,630.27 |
| Equity (Book Value) | 379.71B |
| Book Value Per Share | 57,331.23 |
| Working Capital | 1.46B |
Cash Flow
In the last 12 months, operating cash flow was 68.92 billion and capital expenditures -14.68 billion, giving a free cash flow of 54.24 billion.
| Operating Cash Flow | 68.92B |
| Capital Expenditures | -14.68B |
| Depreciation & Amortization | 20.09B |
| Net Borrowing | 47.62B |
| Free Cash Flow | 54.24B |
| FCF Per Share | 8,274.11 |
Margins
Gross margin is 60.05%, with operating and profit margins of 7.61% and 8.44%.
| Gross Margin | 60.05% |
| Operating Margin | 7.61% |
| Pretax Margin | 4.81% |
| Profit Margin | 8.44% |
| EBITDA Margin | 15.85% |
| EBIT Margin | 7.61% |
| FCF Margin | 22.23% |
Dividends & Yields
This stock pays an annual dividend of 1,200.00, which amounts to a dividend yield of 1.44%.
| Dividend Per Share | 1,200.00 |
| Dividend Yield | 1.44% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 43.33% |
| Buyback Yield | 13.18% |
| Shareholder Yield | 14.65% |
| Earnings Yield | 3.52% |
| FCF Yield | 9.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Medy-Tox is 124,750.00, which is 46.77% higher than the current price. The consensus rating is "Hold".
| Price Target | 124,750.00 |
| Price Target Difference | 46.77% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.83% |
| EPS Growth Forecast (3Y) | 42.75% |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Medy-Tox has an Altman Z-Score of 4.52 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.52 |
| Piotroski F-Score | 5 |